Hormonal therapy in early and advanced breast cancer.
While some of the most intriguing data on the development of hormonal therapy for breast cancer have come from studies on aromatase inhibitors (AIs), few trials have compared these agents directly, with the exception of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Based on the latest results from this trial and on previous investigations of other AIs, a proposed sequence of hormonal therapies (including anastrozole, tamoxifen, letrozole, fulvestrant, and megestrol acetate) for the treatment of breast cancer is beginning to emerge for various patient populations.
Buzdar
Aman U
AU
The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA.
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D018849:Controlled Clinical Trials as Topic; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077289:Letrozole; D019290:Megestrol Acetate / Q000627:therapeutic use; D009570:Nitriles / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014481:United States
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D000077289:Letrozole; D019290:Megestrol Acetate